CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer.
  
  LEARNING OBJECTIVES

  • Appraise published research on the optimal management of biochemical recurrence after local treatment for prostate cancer, and counsel appropriate patients regarding the potential benefits of systemic therapy.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents for the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options.
  • Explore available data with treatment intensification using cytotoxic therapy, secondary hormonal therapy or a combination of these approaches for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into current clinical management algorithms.
  • Assess the available research database supporting PARP inhibitors as monotherapy or in combination with androgen receptor pathway inhibitors for patients with metastatic CRPC (mCRPC) harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical treatment algorithms.
  • Appreciate available Phase III data documenting the efficacy of PSMA-targeted radioligand therapy for patients with PSMA-positive mCRPC, and consider the current and future clinical role of this strategy.
  • Understand the rationale for the evaluation of immune checkpoint inhibitor therapy in combination with multikinase inhibition for patients with mCRPC, and recognize emerging research findings with this novel therapeutic approach.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCOGU24/Prostate/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Rahul Aggarwal, MD
  Professor of Medicine
  Director, Genitourinary Medical Oncology
  University of California, San Francisco
  Department of Medicine
  Division of Hematology/Oncology
  Associate Director for Clinical Research
  UCSF Helen Diller Family Comprehensive Cancer Center
  San Francisco, California
  
  No relevant conflicts of interest to disclose.
  
  Emmanuel S Antonarakis, MD
  Clark Endowed Professor of Medicine
  Division of Hematology, Oncology and Transplantation
  University of Minnesota
  Minneapolis, Minnesota
  
  Advisory Committees: Aadi Bioscience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Curium, Janssen Biotech Inc, Merck, Pfizer Inc, Sanofi, Tango Therapeutics, Tempus; Consulting Agreements: EcoR1 Capital LLC, HOOKIPA Pharma Inc, Lilly, Menarini Silicon Biosystems, Z-Alpha; Contracted Research: Astellas, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Clovis Oncology, MacroGenics Inc, Merck, Novartis, Orion Corporation, Seagen Inc; Patent Holder: QIAGEN.
  
  Elisabeth I Heath, MD
  Associate Center Director, Translational Sciences
  Chair, Genitourinary Oncology Multidisciplinary Team
  Professor of Oncology and Medicine
  Hartmann Endowed Chair for Prostate Cancer Research
  Director, Prostate Cancer Research
  Karmanos Cancer Institute
  Wayne State University School of Medicine
  Detroit, Michigan
  
  Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Sanofi; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Sanofi; Contracted Research: Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics Inc, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Corcept Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Five Prime Therapeutics Inc, Fortis Therapeutics, Gilead Sciences Inc, GSK, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeosTherapeutics, Janssen Biotech Inc, Merck, Mirati Therapeutics Inc, Modra Pharmaceuticals, MSD, Novartis, Oncolys BioPharma, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Seagen Inc; Honoraria/Paid Travel: Astellas, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Sanofi, Seagen Inc; Speakers Bureau: Sanofi; Nonrelevant Financial Relationship: Calibr.
  
  A Oliver Sartor, MD
  Chief, Genitourinary Cancers Disease Group
  Director of Radiopharmaceutical Clinical Trials
  Mayo Clinic
  Rochester, Minnesota
  
  Consulting Agreements: Fusion Pharmaceuticals, ITM Isotopen Technologien München AG, Janssen Biotech Inc, NorthStar Rx LLC, Novartis, Pfizer Inc, POINT Biopharma, Sanofi, Telix Pharmaceuticals Limited, TeneoBio; Consulting or Advisory Roles: Advanced Accelerator Applications, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clarity Pharmaceuticals, Fusion Pharmaceuticals, ITM Isotopen Technologien München AG, Janssen Biotech Inc, NorthStar Rx LLC, Novartis, Pfizer Inc, POINT Biopharma, Sanofi, Telix Pharmaceuticals Limited, TeneoBio; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, Merck, Pfizer Inc; Research Funding to Institution: Advanced Accelerator Applications, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Invitae, Janssen Biotech Inc, Lantheus, Merck, Novartis, Progenics Pharmaceuticals Inc, TeneoBio; Stock Options/Ownership — Public Companies: Abbott Laboratories, AbbVie Inc, Fusion Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Lantheus, Lilly, Pfizer Inc, Telix Pharmaceuticals Limited; Nonrelevant Financial Relationships: ARTBIO, Convergent Therapeutics Inc, Curadh, Ratio Therapeutics.
  
  MODERATOR
  Alan H Bryce, MD
  Chief Clinical Officer
  Professor of Medical Oncology and Therapeutics Research
  Professor of Molecular Medicine, TGen
  City of Hope
  Phoenix, Arizona
  
  Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Gilead Sciences Inc, Lantheus, Merck, Myovant Sciences, Novartis, Pfizer Inc; Consulting Agreement: MOMA therapeutics; Contracted Research: Astellas, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: Lantheus.
  
  SURVEY PARTICIPANTS
  Andrew J Armstrong, MD, ScM — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Clovis Oncology, Exelixis Inc, GoodRx, Merck, Myovant Sciences, Novartis, Pfizer Inc, Z-Alpha; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Dendreon Pharmaceuticals Inc, Epic Sciences, Exact Sciences Corporation, Exelixis Inc, Forma Therapeutics, GoodRx, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc, Z-Alpha; Contracted Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Dendreon Pharmaceuticals Inc, Forma Therapeutics, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc; Nonrelevant Financial Relationships: National Cancer Institute, National Institutes of Health, Prostate Cancer Foundation/Movember, US Department of Defense. Rana R McKay, MD — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: AstraZeneca Pharmaceuticals LP, ArteraAI, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Exelixis Inc, Oncternal Therapeutics.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Merck, and Novartis.
  
  Release date: February 2024
  Expiration date: February 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.